![]() ![]() ![]() Importantly, most people don’t need to be on three medicines for their asthma or COPD. Trimbow and Breztri which are pressurised metered dose inhalers (pMDIs) Trelegy and Enerzair which are dry powder inhalers (DPIs) People in this situation get less benefit than those with device consistencyĬurrently there are four different triple therapy inhalers: Many people with more than one inhaler have a mixture of device types which require different techniques, e.g.Taking medicines in one rather than two inhalers means it is more likely people will remember to take all the prescribed doses every day.Buying one product rather than two is a cheaper way to get the same medicines.Very large research studies involving many thousands of patients show better disease control for people on SITT, when compared to either ICS+LABA or LABA+LAMA.People on three medicines usually have two different inhalers. The most common combination inhalers at the moment have ICS and LABA (e.g. Most people with asthma or COPD take at least one of these. a long-acting beta2 agonist (LABA) which is also to help open the airways.a long-acting muscarinic antagonist (LAMA) which helps open the airways.an inhaled corticosteroid (ICS) to help reduce inflammation.Single inhaler triple therapy (SITT) means one inhaler that contains three different drug types. We asked Clinical Nurse Consultant Brooke Kyle and Asthma Educator Sara Coleman from Sir Charles Gairdner Hospital talk about this positive change. However, things have been changing recently with more manufacturers bringing out single inhaler triple therapies (SITT). Adding another medicine may mean learning a new inhaler technique, and usually means having to spend more money at the pharmacy. Article provided by the Sir Charles Gairdner Hospital Respiratory Team.įor people with asthma and COPD, the world of inhalers seems to get increasingly complicated. ![]()
0 Comments
Leave a Reply. |